Mitsubishi Tanabe Pharma America | LinkedIn (original) (raw)

About us

We are taking on the challenges of complex and debilitating conditions and are committed to meeting the needs of people suffering from serious and often life-threatening illnesses. Today, we are focused on driving scientific discovery in many areas. Our focus remains on bringing treatment to people living with ALS as we strive to make a meaningful difference in their lives. Many people living with amyotrophic lateral sclerosis (ALS) have unmet medical needs. We are committed to doing our best to find solutions that may help address those needs. We continue to expand our work to deepen our understanding of ALS, explore potential biomarkers to aid in further research and seek new answers. Every day we tackle tough challenges in science and medicine. Our teams work diligently to develop smart options that will enable healthcare providers to offer safe and effective treatments for devastating illnesses. Please see our LinkedIn community guidelines here: http://www.mt-pharma-america.com/pdf/LinkedIn-Community-Guidelines.pdf

Industry

Pharmaceutical Manufacturing

Company size

51-200 employees

Headquarters

Jersey City, NJ

Type

Privately Held

Founded

2016

Specialties

pharmaceutical products, amyotrophic lateral sclerosis, rare disease, innovation, research and development, and global business

Locations

Employees at Mitsubishi Tanabe Pharma America

Updates

This #VeteransDay we recognize those who have served in our nation’s military that now live with #ALS. Michael Flanagan, a U.S. Veteran living with this disease shares his story to help spread #ALSawareness. Thank you for your service!
Join us at the Decentralized Trials & Research Alliance (DTRA) 2024 Annual Meeting! We're excited to announce that Sharon Tamir, Senior Director, Digital Healthcare Innovation Business & Research Strategy, MTPA will be presenting at the Decentralized Trials & Research Alliance (DTRA) 2024 Annual Meeting on November 14! Sharon will share key insights and lessons learned from our "Go Digital" study, a remote-decentralized study paired with longitudinal clinic-entered registry data (MOVR study #MDA) for people with ALS. #DTRA2024
Excited to speak at the @DTRA2024 Annual Meeting in Boston on November 13-16! I'll present "The Go-Digital, a DCT Study: Monitoring Activity and fine motor skills assessment in people with ALS." I look forward to helping drive our shared mission of adopting decentralized methods in the community. #decentralizedclinicaltrials #DTRA2024
We’re honored to sponsor the Caregiver Action Network’s #NationalFamilyCaregiversMonth campaign. The theme this year is “I Care…” which aims to highlight the importance of self-recognition and self-identity, an element of caregiving that we know is a significant barrier to caregivers accessing the information and resources necessary to support them throughout their caregiver journey. Learn more about I Care here: https://bit.ly/3BtVftS
This #NationalFirstRespondersDay, we honor those dedicated to serving our communities, like Ken Sutcliffe, a former firefighter living with #ALS. Now, Ken serves in a different way by sharing his ALS story and spreading awareness of the disease. Learn more about his story here: bit.ly/3NoZwS2
Real-world data (#RWD) can help advance patient care strategies in rare diseases like #ALS. Explore our latest RWD findings on treatment outcomes and long-term function at #NEALS2024. Learn more: https://bit.ly/3YlTTtg
At the AMCP Nexus Annual Conference, our team is eager to present our latest research on healthcare resource utilization and connect with colleagues. Read more about our research here: https://bit.ly/4h13he7 #AMCPNexus

Join now to see what you are missing

Join now